Unveiling Haloperidol's Impact: A Case Report on Induced Parkinsonism and Extrapyramidal Symptoms
Abstract
Strong antipsychotic haloperidol is effective in treating delusions and hallucinations, but because of its strong antipsychotic properties, there is an increased extrapyramidal risk symptoms (EPS). We present the EPS case of a 39-year-old male who developed a delusional illness four weeks after injectable haloperidol treatment. Inj. promethazine (phenergan) 25 mg over a week was used to treat symptoms such as diminished movement and muscle stiffness. Frequent medical examinations are essential to halting the course of adverse events and improving both the financial and medical results. Accurate diagnosis, medication cessation, risk factor reduction, and supportive care are all part of primary management. Taking into account the EPS propensity of first-generation antipsychotics, some patient characteristics may indicate that second-generation medicines are better. The goal of this strategy is to minimize the EPS burden while optimizing efficacy.
Full text article
References
López-Sendón J, Mena MA, de Yébenes JG. Drug-induced parkinsonism. Expert Opin Drug Saf. 2013 Jul;12(4):487-96. doi: 10.1517/14740338.2013.787065. Epub 2013 Mar 31. PMID: 23540800.
Shin HW, Chung SJ. Drug-induced parkinsonism. J Clin Neurol 2012;8: 15e21.
Rajaram C, Reddy KR, Sekhar KBC. Neuroprotective activity of Tephrosia purpurea against haloperidol induced Parkinson disease model. Pharmacologia 2015;6(4):125e30.
Khot VK, Egan MF, Hyde T, Wyatt RJ. In: Lang AE, Weiner WJ, editors. In: drug induced movement disorders. Mount Kisco, NY: Futura Publishing Co; 1992. p. 121e61. Neuroleptics and classic tardive dyskinesia.
Perera J, Tan JH, Jeevathayaparan S, Chakravarthi S, Haleagrahara N. Neuroprotective effects of alpha lipoic acid on haloperidol-induced oxidative stress in the rat brain. Cell Biosci 2011;1:2e6.
Mosley RL, Benner EJ, Kadiu I, Thomas M, Boska MD, Khader Hasan, et al. Neuroinflammation, oxidative stress and the pathogenesis of Parkinson’s disease. Clin Neurosci Res 2006;6(5):261e81.
Shivakumar BR, Ravindranath V. Oxidative stress and thiol modification induced by chronic administration of haloperidol. J Pharmacol Exp Therapeut 1993;265:1137e41.
Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999;52(6):1214-20.
Barbosa MT, Caramelli P, Maia DP, et al. Parkinsonism and Parkinson’s disease in the elderly: a community-based survey in Brazil (the Bambui study). Mov Disord 2006;21(6):800-8.
Chaithra S, Ammu A, Eapen BA, Hemalatha S and Sivakumar T: Haloperidol induced neuroleptic malignant syndrome. Int. J. Pharm. Sci. Rev. Res. 2016; 39(2): 145- 6.
Chean MF and Liew KB: A case report on haloperidol induced neuroleptic malignant syndrome. Journal of Clinical Psychiatry 2013; 7: 22-25.
Froemming JS, Lam YW, Jann MW and Davis CM: Pharmacokinetics of haloperidol. Clin Pharmacokinet 1989; 17: 396-423.